Draft Infection Control in Healthcare Personnel: Epidemiology and Control of Selected Infections Transmitted Among Healthcare Personnel and Patients: Measles, Mumps, Rubella, and Varicella-Zoster Virus Sections, 45906-45907 [2023-15175]
Download as PDF
45906
Federal Register / Vol. 88, No. 136 / Tuesday, July 18, 2023 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2023–0062]
Draft Infection Control in Healthcare
Personnel: Epidemiology and Control
of Selected Infections Transmitted
Among Healthcare Personnel and
Patients: Measles, Mumps, Rubella,
and Varicella-Zoster Virus Sections
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), in the
Department of Health and Human
Services (HHS), announces the opening
of a docket to obtain comment on the
Draft Infection Control in Healthcare
Personnel: Epidemiology and Control of
Selected Infections Transmitted Among
Healthcare Personnel and Patients:
Measles, Mumps, Rubella, and
Varicella-Zoster Virus Sections (‘‘Draft
Guideline: Measles, Mumps, Rubella,
and Varicella-Zoster Virus Sections’’).
The Draft Guideline: Measles, Mumps,
Rubella, and Varicella-Zoster Virus
Sections updates the Guideline for
infection control in health care
personnel, 1998 (‘‘1998 Guideline’’),
Part E: Epidemiology and Control of
Selected Infections Transmitted Among
Health Care Personnel and Patients, and
its corresponding recommendations in
Part II of the 1998 Guideline: ‘‘8.
Measles;’’ ‘‘10. Mumps;’’ ‘‘15. Rubella;’’
and ‘‘21. Varicella.’’ The updated
recommendations in the Draft
Guideline: Measles, Mumps, Rubella,
and Varicella-Zoster Virus Sections are
intended for use by the leaders and staff
of healthcare facilities and systems’
Occupational Health Services (OHS), as
further provided herein. These updated
recommendations will help facilitate the
provision of occupational infection
prevention and control services to
healthcare personnel (HCP) who have
been exposed or infected and may be
contagious to others in the workplace.
DATES: Written comments must be
received on or before September 18,
2023.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2023–
0062 by either of the methods listed
below. Do not submit comments by
email. CDC does not accept comments
by email.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
19:16 Jul 17, 2023
Jkt 259001
• Mail: Healthcare Infection Control
Practices Advisory Committee (HICPAC)
Secretariat, Division of Healthcare
Quality Promotion, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop H16–3, Atlanta,
Georgia 30329, Attn: Docket Number
CDC–2023–0062.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to https://regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Laura Wells, Division of Healthcare
Quality Promotion, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop H16–2, Atlanta,
Georgia 30329; Telephone: (404) 639–
4000.
SUPPLEMENTARY INFORMATION:
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data related to the Draft Guideline:
Measles, Mumps, Rubella, and
Varicella-Zoster Virus Sections.
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comment or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information such
as Social Security numbers, medical
information, inappropriate language, or
duplicate/near duplicate examples of a
mass-mail campaign. Do not submit
comments by email. CDC does not
accept comments by email.
Background
The Draft Guideline: Measles, Mumps,
Rubella, and Varicella-Zoster Virus
Sections, located in the ‘‘Supporting &
Related Material’’ tab of the docket,
updates the Guideline for infection
control in health care personnel, 1998,
Part E: Epidemiology and Control of
Selected Infections Transmitted Among
Health Care Personnel and Patients, and
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
its corresponding recommendations in
Part II of the 1998 Guideline: ‘‘8.
Measles;’’ ‘‘10. Mumps;’’ ‘‘15. Rubella;’’
and ‘‘21. Varicella.’’ The 1998 Guideline
provided information and
recommendations for Occupational
Health Services (OHS) of healthcare
facilities and systems on the prevention
of transmission of infectious diseases
among healthcare personnel (HCP) and
patients and can be found at https://
stacks.cdc.gov/view/cdc/11563.
As described in the Executive
Summary of this guideline (https://
www.cdc.gov/infectioncontrol/
guidelines/healthcare-personnel/execsummary.html), in this document,
‘‘OHS’’ is used synonymously with
‘‘Employee Health,’’ ‘‘Employee Health
Services,’’ ‘‘Employee Health and
Safety,’’ ‘‘Occupational Health,’’ and
other such programs. OHS refers to the
group, department, or program that
addresses many aspects of health and
safety in the workplace for HCP,
including the provision of clinical
services for work-related injuries,
exposures, and illnesses. In healthcare
settings, OHS addresses workplace
hazards including communicable
diseases; slips, trips, and falls; patient
handling injuries; chemical exposures;
HCP burnout; and workplace violence.
This Draft Guideline: Measles,
Mumps, Rubella, and Varicella-Zoster
Virus Sections update is part of a larger
guideline update: Infection Control in
Healthcare Personnel. Part I,
Infrastructure and Routine Practices for
Occupational Infection Prevention and
Control Services (2019), and the
Diphtheria, Group A Streptococcus,
Meningococcal Disease, Pertussis, and
Rabies sections of Part II, Epidemiology
and Control of Selected Infections
Transmitted Among Healthcare
Personnel and Patients (2022) are
complete and have been published on
the CDC Infection Control Guideline
website: https://www.cdc.gov/
infectioncontrol/guidelines/healthcarepersonnel/. The Draft
Guideline: Measles, Mumps, Rubella,
and Varicella-Zoster Virus Sections,
once finalized, is intended for use by
the leaders and staff of OHS to guide the
management of exposed or infected HCP
who may be contagious to others in the
workplace. The draft recommendations
in Draft Guideline: Measles, Mumps,
Rubella, and Varicella-Zoster Virus
Sections update the 1998
recommendations with current guidance
on the management of HCP exposed to
or potentially infected with measles,
mumps, rubella, or varicella-zoster
virus, focusing on postexposure
management, including postexposure
E:\FR\FM\18JYN1.SGM
18JYN1
Federal Register / Vol. 88, No. 136 / Tuesday, July 18, 2023 / Notices
prophylaxis, for exposed HCP and work
restrictions for exposed or infected HCP.
Since 2015, the Healthcare Infection
Control Practices Advisory Committee
(HICPAC) has worked with national
partners, academicians, public health
professionals, healthcare providers, and
other partners to develop Infection
Control in Healthcare Personnel
(https://www.cdc.gov/infectioncontrol/
guidelines/healthcare-personnel/
index.html) as a segmental update of the
1998 Guideline. HICPAC is a Federal
advisory committee appointed to
provide advice and guidance to HHS
and CDC regarding the practice of
infection control and strategies for
surveillance, prevention, and control of
healthcare-associated infections,
antimicrobial resistance, and related
events in United States healthcare
settings. HICPAC includes
representatives from public health,
infectious diseases, regulatory and other
Federal agencies, professional societies,
and others impacted. Draft Guideline:
Measles, Mumps, Rubella, and
Varicella-Zoster Virus Sections, once
finalized, will be the next sections to be
posted to the Infection Control in
Healthcare Personnel website.
The updated draft recommendations
in Draft Guideline: Measles, Mumps,
Rubella, and Varicella-Zoster Virus
Sections are informed by reviews of the
1998 Guideline; CDC resources (e.g.,
CDC infection control website),
guidance, and guidelines, as noted more
specifically in the draft document; and
new scientific evidence, when available.
CDC is seeking comments on the Draft
Guideline: Measles, Mumps, Rubella,
and Varicella-Zoster Virus Sections.
Please provide references to new
evidence and justification to support
any suggested revisions or additions.
This Draft Guideline: Measles, Mumps,
Rubella, and Varicella-Zoster Virus
Sections is not a Federal rule or
regulation.
Dated: July 13, 2023.
Tiffany Brown,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2023–15175 Filed 7–17–23; 8:45 am]
ddrumheller on DSK120RN23PROD with NOTICES1
BILLING CODE 4163–18–P
VerDate Sep<11>2014
19:16 Jul 17, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS 3444–PN]
Medicare Program; Application by The
Joint Commission (TJC) for Continued
CMS Approval of Its Home Infusion
Therapy (HIT) Accreditation Program
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice with comment.
AGENCY:
This notice acknowledges the
receipt of an application from The Joint
Commission (TJC) for continued
recognition as a national accrediting
organization providing home infusion
therapy (HIT) services that wish to
participate in the Medicare or Medicaid
programs. The statute requires that
within 60 days of receipt of an
organization’s complete application, the
Centers for Medicare & Medicaid
Services (CMS) publish a notice that
identifies the national accrediting body
making the request, describes the nature
of the request, and provides at least a
30-day public comment period.
DATES: To be assured consideration,
comments must be received at one of
the addresses provided below, by
August 16, 2023.
ADDRESSES: In commenting, refer to file
code CMS–3444–PN.
Comments, including mass comment
submissions, must be submitted in one
of the following three ways (please
choose only one of the ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
2. By regular mail. You may mail
written comments to the following
address ONLY: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–3444–PN, P.O. Box 8016,
Baltimore, MD 21244–8010.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
following address ONLY: Centers for
Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–3444–PN,
Mail Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
For information on viewing public
comments, see the beginning of the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Shannon Freeland, (410) 786–4348.
SUMMARY:
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
45907
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All
comments received before the close of
the comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following
website as soon as possible after they
have been received: https://
www.regulations.gov. Follow the search
instructions on that website to view
public comments. We will not post on
Regulations.gov public comments that
make threats to individuals or
institutions or suggest that the
individual will take actions to harm the
individual. We continue to encourage
individuals not to submit duplicative
comments. We will post acceptable
comments from multiple unique
commenters even if the content is
identical or nearly identical to other
comments.
I. Background
Home infusion therapy (HIT) is a
treatment option for Medicare
beneficiaries with a wide range of acute
and chronic conditions. Section 5012 of
the 21st Century Cures Act (Pub. L. 114–
255, enacted December 13, 2016) added
section 1861(iii) to the Social Security
Act (the Act), establishing a new
Medicare benefit for HIT services.
Section 1861(iii)(1) of the Act defines
‘‘home infusion therapy’’ as professional
services, including nursing services;
training and education not otherwise
covered under the Durable Medical
Equipment (DME) benefit; remote
monitoring; and other monitoring
services. Home infusion therapy must
be furnished by a qualified HIT supplier
and furnished in the individual’s home.
The individual must:
• Be under the care of an applicable
provider (that is, physician, nurse
practitioner, or physician assistant); and
• Have a plan of care established and
periodically reviewed by a physician in
coordination with the furnishing of
home infusion drugs under Part B, that
prescribes the type, amount, and
duration of infusion therapy services
that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act
requires that a qualified HIT supplier be
accredited by an accrediting
organization (AO) designated by the
Secretary in accordance with section
1834(u)(5) of the Act. Section
1834(u)(5)(A) of the Act identifies
factors for designating AOs and in
reviewing and modifying the list of
designated AOs. These statutory factors
are as follows:
E:\FR\FM\18JYN1.SGM
18JYN1
Agencies
[Federal Register Volume 88, Number 136 (Tuesday, July 18, 2023)]
[Notices]
[Pages 45906-45907]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-15175]
[[Page 45906]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2023-0062]
Draft Infection Control in Healthcare Personnel: Epidemiology and
Control of Selected Infections Transmitted Among Healthcare Personnel
and Patients: Measles, Mumps, Rubella, and Varicella-Zoster Virus
Sections
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), in the
Department of Health and Human Services (HHS), announces the opening of
a docket to obtain comment on the Draft Infection Control in Healthcare
Personnel: Epidemiology and Control of Selected Infections Transmitted
Among Healthcare Personnel and Patients: Measles, Mumps, Rubella, and
Varicella-Zoster Virus Sections (``Draft Guideline: Measles, Mumps,
Rubella, and Varicella-Zoster Virus Sections''). The Draft Guideline:
Measles, Mumps, Rubella, and Varicella-Zoster Virus Sections updates
the Guideline for infection control in health care personnel, 1998
(``1998 Guideline''), Part E: Epidemiology and Control of Selected
Infections Transmitted Among Health Care Personnel and Patients, and
its corresponding recommendations in Part II of the 1998 Guideline:
``8. Measles;'' ``10. Mumps;'' ``15. Rubella;'' and ``21. Varicella.''
The updated recommendations in the Draft Guideline: Measles, Mumps,
Rubella, and Varicella-Zoster Virus Sections are intended for use by
the leaders and staff of healthcare facilities and systems'
Occupational Health Services (OHS), as further provided herein. These
updated recommendations will help facilitate the provision of
occupational infection prevention and control services to healthcare
personnel (HCP) who have been exposed or infected and may be contagious
to others in the workplace.
DATES: Written comments must be received on or before September 18,
2023.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2023-
0062 by either of the methods listed below. Do not submit comments by
email. CDC does not accept comments by email.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Healthcare Infection Control Practices Advisory
Committee (HICPAC) Secretariat, Division of Healthcare Quality
Promotion, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, Mailstop H16-3, Atlanta, Georgia 30329, Attn: Docket Number
CDC-2023-0062.
Instructions: All submissions received must include the agency name
and Docket Number. All relevant comments received will be posted
without change to https://regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Laura Wells, Division of Healthcare
Quality Promotion, Centers for Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H16-2, Atlanta, Georgia 30329; Telephone:
(404) 639-4000.
SUPPLEMENTARY INFORMATION:
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data related to the
Draft Guideline: Measles, Mumps, Rubella, and Varicella-Zoster Virus
Sections.
Please note that comments received, including attachments and other
supporting materials, are part of the public record and are subject to
public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your
comment or supporting materials that you consider confidential or
inappropriate for public disclosure. If you include your name, contact
information, or other information that identifies you in the body of
your comments, that information will be on public display. CDC will
review all submissions and may choose to redact, or withhold,
submissions containing private or proprietary information such as
Social Security numbers, medical information, inappropriate language,
or duplicate/near duplicate examples of a mass-mail campaign. Do not
submit comments by email. CDC does not accept comments by email.
Background
The Draft Guideline: Measles, Mumps, Rubella, and Varicella-Zoster
Virus Sections, located in the ``Supporting & Related Material'' tab of
the docket, updates the Guideline for infection control in health care
personnel, 1998, Part E: Epidemiology and Control of Selected
Infections Transmitted Among Health Care Personnel and Patients, and
its corresponding recommendations in Part II of the 1998 Guideline:
``8. Measles;'' ``10. Mumps;'' ``15. Rubella;'' and ``21. Varicella.''
The 1998 Guideline provided information and recommendations for
Occupational Health Services (OHS) of healthcare facilities and systems
on the prevention of transmission of infectious diseases among
healthcare personnel (HCP) and patients and can be found at https://stacks.cdc.gov/view/cdc/11563.
As described in the Executive Summary of this guideline (https://www.cdc.gov/infectioncontrol/guidelines/healthcare-personnel/exec-summary.html), in this document, ``OHS'' is used synonymously with
``Employee Health,'' ``Employee Health Services,'' ``Employee Health
and Safety,'' ``Occupational Health,'' and other such programs. OHS
refers to the group, department, or program that addresses many aspects
of health and safety in the workplace for HCP, including the provision
of clinical services for work-related injuries, exposures, and
illnesses. In healthcare settings, OHS addresses workplace hazards
including communicable diseases; slips, trips, and falls; patient
handling injuries; chemical exposures; HCP burnout; and workplace
violence.
This Draft Guideline: Measles, Mumps, Rubella, and Varicella-Zoster
Virus Sections update is part of a larger guideline update: Infection
Control in Healthcare Personnel. Part I, Infrastructure and Routine
Practices for Occupational Infection Prevention and Control Services
(2019), and the Diphtheria, Group A Streptococcus, Meningococcal
Disease, Pertussis, and Rabies sections of Part II, Epidemiology and
Control of Selected Infections Transmitted Among Healthcare Personnel
and Patients (2022) are complete and have been published on the CDC
Infection Control Guideline website: https://www.cdc.gov/infectioncontrol/guidelines/healthcare-personnel/. The Draft
Guideline: Measles, Mumps, Rubella, and Varicella-Zoster Virus
Sections, once finalized, is intended for use by the leaders and staff
of OHS to guide the management of exposed or infected HCP who may be
contagious to others in the workplace. The draft recommendations in
Draft Guideline: Measles, Mumps, Rubella, and Varicella-Zoster Virus
Sections update the 1998 recommendations with current guidance on the
management of HCP exposed to or potentially infected with measles,
mumps, rubella, or varicella-zoster virus, focusing on postexposure
management, including postexposure
[[Page 45907]]
prophylaxis, for exposed HCP and work restrictions for exposed or
infected HCP.
Since 2015, the Healthcare Infection Control Practices Advisory
Committee (HICPAC) has worked with national partners, academicians,
public health professionals, healthcare providers, and other partners
to develop Infection Control in Healthcare Personnel (https://www.cdc.gov/infectioncontrol/guidelines/healthcare-personnel/) as a segmental update of the 1998 Guideline. HICPAC is a
Federal advisory committee appointed to provide advice and guidance to
HHS and CDC regarding the practice of infection control and strategies
for surveillance, prevention, and control of healthcare-associated
infections, antimicrobial resistance, and related events in United
States healthcare settings. HICPAC includes representatives from public
health, infectious diseases, regulatory and other Federal agencies,
professional societies, and others impacted. Draft Guideline: Measles,
Mumps, Rubella, and Varicella-Zoster Virus Sections, once finalized,
will be the next sections to be posted to the Infection Control in
Healthcare Personnel website.
The updated draft recommendations in Draft Guideline: Measles,
Mumps, Rubella, and Varicella-Zoster Virus Sections are informed by
reviews of the 1998 Guideline; CDC resources (e.g., CDC infection
control website), guidance, and guidelines, as noted more specifically
in the draft document; and new scientific evidence, when available. CDC
is seeking comments on the Draft Guideline: Measles, Mumps, Rubella,
and Varicella-Zoster Virus Sections. Please provide references to new
evidence and justification to support any suggested revisions or
additions. This Draft Guideline: Measles, Mumps, Rubella, and
Varicella-Zoster Virus Sections is not a Federal rule or regulation.
Dated: July 13, 2023.
Tiffany Brown,
Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2023-15175 Filed 7-17-23; 8:45 am]
BILLING CODE 4163-18-P